title: CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
abstract: The purpose of this study was to evaluate the importance of biological markers to predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) in patients with locally advanced triple-negative breast cancers (TNBCs). Forty-one patients (18.6%) among 220 breast cancer patients were identified as TNBCs from March 2006 to 2009 were included in this prospective study. The pre-NCT treatment expression levels of Ki-67 proliferation index, estrogen receptor (ER), progesterone receptor (PgR), epidermal growth factor receptor 2 (HER-2), CK5/6, epidermal growth factor receptor (EGFR), cyclin D1, and nm23-H1 were detected by immunohistochemistry (IHC). A total of 180 cycles were administered with the median number of four cycles per patient (range, 4-6). The pCR rate was 34.1% (95% CI, 19.6-48.6%). In univariate analysis, early T stage, clinical response after 2 cycles, negative basal-like, negative EGFR, high Ki-67 proliferation index, and positive nm23-H1 were found to be significantly predictive of a pCR (P = 0.010, 0.040, 0.007, 0.001, 0.019, and 0.010, respectively). Basal-like status and nm23-H1 status were significant for pCR on multivariate analysis (P = 0.004 and 0.031, respectively). Basal-like status and nm23-H1 are independent predictive factors of pCR to neoadjuvant docetaxel plus epirubicin combination chemotherapy in patients with TNBCs.
authors.affiliation: Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese People's Liberation Army, No 28, Fuxing Rd, 100853 Beijing, People's Republic of China. lixr301@163.com
authors.forename: Xi-ru
authors.initials: XR
authors.lastname: Li
authors.forename: Mei
authors.initials: M
authors.lastname: Liu
authors.forename: Yan-jun
authors.initials: YJ
authors.lastname: Zhang
authors.forename: Jian-dong
authors.initials: JD
authors.lastname: Wang
authors.forename: Yi-qiong
authors.initials: YQ
authors.lastname: Zheng
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Bing
authors.initials: B
authors.lastname: Ma
authors.forename: Xin
authors.initials: X
authors.lastname: Song
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D019938:Cyclin D1 / Q000378:metabolism; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053555:Keratin-5 / Q000378:metabolism; D053553:Keratin-6 / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism*; D008875:Middle Aged; D054778:NM23 Nucleoside Diphosphate Kinases / Q000378:metabolism*; D020360:Neoadjuvant Therapy / Q000379:methods*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C530104:CCND1 protein, human; D053555:Keratin-5; D053553:Keratin-6; D019394:Ki-67 Antigen; D054778:NM23 Nucleoside Diphosphate Kinases; D019938:Cyclin D1; C512478:EGFR protein, human; D066246:ErbB Receptors; C517938:NME1 protein, human